Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Protara Therapeutics, Inc. (TARA)
USD4.06
+0.02 (+0.50%)
US NASDAQ Healthcare Biotechnology
Address
345 Park Avenue South 10010
New York City, NY, US
New York City, NY, US
CEO
Jesse Shefferman
Website
protaratx.com
IPO
2014-10-22
CIK 1359931 ISIN US74365U1079
Description
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Nasdaq | PRTO | 2019-11-06 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.06
+0.02 (+0.50%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
732.3K
Beta
1.45
Float Shares
33.82M
Free Float %
87.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.97% | -2.62% | +2.56% | -20.12% | -1.33% | -2.44% | +61.49% | +54.30% | -40.09% | -98.20% | -98.70% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
4.06
Low
12.00
+195.6%
Consensus
12.00
+195.6%
Median
12.00
+195.6%
High
12.00
+195.6%
DCF (Unlevered)
1.03
-74.5%
DCF (Levered)
1.08
-73.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
12.00
+195.6%
|
Quality scores
Altman Z-Score
8.63
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+38.3% ★ Q1'26: -6.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-146.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+108.0% Q1'26: +41.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: -0.04× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 6 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 6 Rev. Ana. 4 EPS Ana. |
Dec 2029 5 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 3.22M (-100.0%)
|
—
est: 24.87M (-100.0%)
|
22.30M
22.30M – 22.30M
-10.3% YoY
|
25.33M
25.33M – 25.33M
+13.6% YoY
|
123.76M
123.76M – 123.76M
+388.5% YoY
|
253.63M
253.63M – 253.63M
+104.9% YoY
|
344.88M
344.88M – 344.88M
+36.0% YoY
|
| EBITDA |
-48.82M
|
-64.19M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-49.15M
|
-64.55M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-44.60M
est: -108.15M (+58.8%)
|
-57.44M
est: -57.44M (+0.0%)
|
-67.52M
-79.06M – -55.98M
-17.6% YoY
|
-59.26M
-73.07M – -45.44M
+12.2% YoY
|
-42.11M
-52.64M – -8.26M
+28.9% YoY
|
13.99M
13.99M – 13.99M
+133.2% YoY
|
57.11M
57.11M – 57.11M
+308.2% YoY
|
| SGA |
17.45M
|
21.92M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-2.17
est: -2.20 (+1.4%)
|
-1.34
est: -1.26 (-6.2%)
|
-1.58
-1.85 – -1.31
-25.0% YoY
|
-1.48
-1.71 – -1.06
+6.3% YoY
|
-0.74
-1.23 – -0.19
+49.6% YoY
|
0.33
0.33 – 0.33
+143.9% YoY
|
1.33
1.33 – 1.33
+308.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-29 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-23.41M
OE per share TTM
-3.47
Owner's Yield
-9.65%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
134.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
38
Total invested
42.63M
Insider transactions (90d)
0
Beneficial owners (>5%)
38
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Silverman | 5.04M | 37.79% | — | 2.21M | — | 2.21M | IN | States | 2020-01-21 | ↗ |
| 2 | L.P. | 2.21M | 37.79% | — | 2.21M | — | 2.21M | OO | Delaware | 2020-01-21 | ↗ |
| 3 | Management Inc. | 2.21M | 37.79% | — | 2.21M | — | 2.21M | OO | Massachusetts | 2020-01-21 | ↗ |
| 4 | s | 2.07M | 9.99% | — | 2.07M | — | 2.07M | IA, PN | Delaware | 2024-04-25 | ↗ |
| 5 | Adam Morgan | 2.06M | 5.90% | — | — | — | 2.06M | IN | CAYMAN ISLANDS | 2024-12-17 | ↗ |
| 6 | Balaji Venkataraman | 2.06M | 5.90% | — | — | — | 2.06M | IN | CAYMAN ISLANDS | 2024-12-17 | ↗ |
| 7 | Velan Capital Investment Management LP | 2.06M | 5.90% | — | — | — | 2.06M | PN | CAYMAN ISLANDS | 2024-12-17 | ↗ |
| 8 | Velan Capital Management LLC | 2.06M | 5.90% | — | — | — | 2.06M | OO | CAYMAN ISLANDS | 2024-12-17 | ↗ |
| 9 | Velan Capital Holdings LLC | 2.05M | 5.90% | — | — | — | 2.05M | OO | CAYMAN ISLANDS | 2024-12-17 | ↗ |
| 10 | Velan Capital Master Fund LP | 2.05M | 5.90% | — | — | — | 2.05M | PN | CAYMAN ISLANDS | 2024-12-17 | ↗ |
| 11 | 20-5648796 | 1.68M | 8.15% | — | 1.68M | — | 1.68M | CO | Massachusetts | 2024-11-18 | ↗ |
| 12 | Woodline Partners LP | 1.58M | 7.40% | 1.58M | — | 1.58M | — | IA | Delaware | 2024-11-14 | ↗ |
| 13 | Lathi | 1.52M | 8.60% | — | 1.52M | — | 1.52M | IN | Delaware | 2018-11-06 | ↗ |
| 14 | OrbiMed Capital LLC | 671.7K | 6.00% | 671.7K | — | 671.7K | — | IA | Delaware | 2022-02-11 | ↗ |
| 15 | 2 | 608.5K | 5.80% | — | 608.5K | — | 608.5K | IA | Delaware | 2020-10-01 | ↗ |
| 16 | CVI Investments, Inc. | 600.4K | 5.30% | — | 600.4K | — | 600.4K | CO | Cayman Islands | 2024-04-09 | ↗ |
| 17 | Heights Capital Management, Inc. | 600.4K | 5.30% | — | 600.4K | — | 600.4K | CO | Delaware | 2024-04-09 | ↗ |
| 18 | DRW Holdings, LLC | 448.8K | 7.68% | 448.8K | — | 448.8K | — | OO | Delaware | 2020-01-16 | ↗ |
| 19 | DRW Management LLC | 448.8K | 7.68% | 448.8K | — | 448.8K | — | OO | Delaware | 2020-01-16 | ↗ |
| 20 | DRW Venture Capital LLC | 448.8K | 7.68% | 448.8K | — | 448.8K | — | OO | Delaware | 2020-01-16 | ↗ |
| 21 | Donald R. Wilson, Jr. | 448.8K | 7.68% | 448.8K | — | 448.8K | — | IN | Delaware | 2020-01-16 | ↗ |
| 22 | Advisors LLC | 421.6K | 3.80% | — | 421.6K | — | 421.6K | IA | Delaware | 2022-02-15 | ↗ |
| 23 | Edelman | 421.6K | 3.80% | — | 421.6K | — | 421.6K | IN | Delaware | 2022-02-15 | ↗ |
| 24 | Sciences Master Fund, Ltd. | 421.6K | 3.80% | — | 421.6K | — | 421.6K | CO | Delaware | 2022-02-15 | ↗ |
| 25 | Chart Westcott | 307.3K | 5.30% | — | 307.3K | — | — | HC, IN | Delaware | 2020-02-21 | ↗ |
| 26 | Ikarian Capital, LLC | 307.3K | 5.30% | — | 307.3K | — | — | IA | Delaware | 2020-02-21 | ↗ |
| 27 | Neil Shahrestani | 307.3K | 5.30% | — | 307.3K | — | — | HC, IN | Delaware | 2020-02-21 | ↗ |
| 28 | Ikarian Healthcare Fund GP, L.P. | 260.2K | 4.50% | — | 260.2K | — | — | PN | Delaware | 2020-02-21 | ↗ |
| 29 | Ikarian Healthcare Master Fund, L.P. | 260.2K | 4.50% | — | 260.2K | — | — | PN | Delaware | 2020-02-21 | ↗ |
| 30 | OrbiMed Advisors LLC | 158.9K | 1.40% | — | 158.9K | — | — | IA | Delaware | 2022-02-11 | ↗ |
| 31 | Abingworth Bioventures VI, LP | 113.9K | 1.90% | — | 113.9K | — | — | PN | England | 2020-01-17 | ↗ |
| 32 | Abingworth LLP | 113.9K | 1.90% | — | 113.9K | — | — | PN | England | 2020-01-17 | ↗ |
| 33 | Velan Horizon Fund LP | 5.0K | 1.00% | — | — | — | 5.0K | PN | CAYMAN ISLANDS | 2024-12-17 | ↗ |
| 34 | Velan Horizon GP LLC | 5.0K | 1.00% | — | — | — | 5.0K | OO | CAYMAN ISLANDS | 2024-12-17 | ↗ |
| 35 | 2. | 10.00 | 0.00% | — | 9.2K | — | — | HC, PN | Delaware | 2024-04-22 | ↗ |
| 36 | Rock Springs Capital LLC | — | 0.00% | — | — | — | — | HC, OO | Delaware | 2022-02-15 | ↗ |
| 37 | Rock Springs Capital Management LP | — | 0.00% | — | — | — | — | IA | Delaware | 2022-02-15 | ↗ |
| 38 | Rock Springs Capital Master Fund LP | — | 0.00% | — | — | — | — | PN | Cayman Islands | 2022-02-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
38
-69 vs prev Q
New positions
12
Closed positions
77
Increased
25
Reduced
9
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 35.0K +35.0K (+100.0%) | 186.55M +186.6M (+100.0%) | 0.08% +0.083 pp | 0.16% +0.159 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 2 | EMPERY ASSET MANAGEMENT, LP | 12.8K +12.8K (+100.0%) | 68.40M +68.4M (+100.0%) | 0.03% +0.030 pp | 0.06% +0.060 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 3 | JANUS HENDERSON GROUP PLC | 5.14M +910.3K (+21.5%) | 27.38M +9.0M (+49.1%) | 12.16% +2.153 pp | 0.01% +0.004 pp | USD4.83 +10.4% | 5 qtrs — |
| 4 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 2.83M +695.7K (+32.5%) | 15.11M +5.8M (+62.4%) | 6.71% +1.646 pp | 8.76% +0.025 pp | USD4.23 +26.0% | 7 qtrs — |
| 5 | BLACKROCK, INC. | 2.41M +179.5K (+8.1%) | 12.84M +3.1M (+32.4%) | 5.70% +0.425 pp | 0.00% +0.000 pp | USD3.45 +54.5% | 6 qtrs — |
| 6 | VANGUARD GROUP INC | 2.39M +487.7K (+25.6%) | 12.75M +4.5M (+53.9%) | 5.66% +1.154 pp | 0.00% +0.000 pp | USD6.91 -22.9% | 23 qtrs — |
| 7 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 2.25M +850.0K (+60.7%) | 11.99M +5.9M (+96.9%) | 5.32% +2.011 pp | 0.60% +0.183 pp | USD5.30 +0.6% | 5 qtrs — |
| 8 | BLACKSTONE INC. | 1.91M +— (+0.0%) | 10.18M +1.9M (+22.5%) | 4.52% 0.000 pp | 0.04% +0.007 pp | USD5.05 +5.5% | 5 qtrs — |
| 9 | ACORN CAPITAL ADVISORS, LLC | 1.75M +— (+0.0%) | 9.34M +1.7M (+22.5%) | 4.14% 0.000 pp | 3.16% -0.705 pp | USD4.67 +14.1% | 5 qtrs — |
| 10 | SIO CAPITAL MANAGEMENT, LLC | 1.72M +1.7M (+100.0%) | 9.14M +9.1M (+100.0%) | 4.06% +4.058 pp | 1.44% +1.438 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 11 | CATALIO CAPITAL MANAGEMENT, LP | 1.45M -54.5K (-3.6%) | 7.71M +1.2M (+18.1%) | 3.42% -0.129 pp | 1.36% +0.156 pp | USD4.54 +17.4% | 5 qtrs — |
| 12 | 5AM VENTURE MANAGEMENT, LLC | 1.37M +569.8K (+71.2%) | 7.30M +3.8M (+109.8%) | 3.24% +1.348 pp | 2.30% +1.021 pp | USD5.30 +0.6% | 5 qtrs — |
| 13 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.26M +815.0K (+183.4%) | 6.71M +4.8M (+247.2%) | 2.98% +1.928 pp | 0.05% +0.032 pp | USD4.98 +7.0% | 5 qtrs — |
| 14 | UBS GROUP AG | 1.22M +372.5K (+44.2%) | 6.48M +2.8M (+76.7%) | 2.88% +0.881 pp | 0.00% +0.001 pp | USD4.29 +24.2% | 16 qtrs — |
| 15 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.14M +1.1M (+3,127.4%) | 6.06M +5.9M (+3,854.5%) | 2.69% +2.606 pp | 0.45% +0.431 pp | USD5.33 +0.0% | 5 qtrs — |
| 16 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.04M +1.0M (+100.0%) | 5.56M +5.6M (+100.0%) | 2.47% +2.469 pp | 0.01% +0.008 pp | USD5.33 +0.0% | 5 qtrs — |
| 17 | BAKER BROS. ADVISORS LP | 971.6K +434.8K (+81.0%) | 5.18M +2.8M (+121.8%) | 2.30% +1.029 pp | 0.03% +0.013 pp | USD9.14 -41.7% | 23 qtrs — |
| 18 | CITADEL ADVISORS LLC | 901.5K +399.1K (+79.4%) | 4.81M +2.6M (+119.9%) | 2.13% +0.944 pp | 0.00% +0.000 pp | USD4.25 +25.4% | 20 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 817.2K +58.5K (+7.7%) | 4.36M +1.1M (+32.0%) | 1.93% +0.138 pp | 0.00% +0.000 pp | USD5.33 +0.0% | 23 qtrs — |
| 20 | MAVEN SECURITIES LTD | 754.6K +754.6K (+100.0%) | 4.02M +4.0M (+100.0%) | 1.79% +1.785 pp | 0.09% +0.089 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 21 | MILLENNIUM MANAGEMENT LLC | 753.3K +65.0K (+9.5%) | 4.02M +1.0M (+34.1%) | 1.78% +0.154 pp | 0.00% +0.000 pp | USD4.80 +11.0% | 6 qtrs — |
| 22 | SPHERA FUNDS MANAGEMENT LTD. | 650.0K +650.0K (+100.0%) | 3.46M +3.5M (+100.0%) | 1.54% +1.538 pp | 0.67% +0.670 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 23 | MARSHALL WACE, LLP | 584.5K +298.9K (+104.7%) | 3.12M +1.9M (+150.8%) | 1.38% +0.707 pp | 0.00% +0.002 pp | USD4.21 +26.6% | 3 qtrs — |
| 24 | STATE STREET CORP | 570.9K +220.8K (+63.1%) | 3.04M +1.5M (+99.8%) | 1.35% +0.522 pp | 0.00% +0.000 pp | USD4.72 +12.9% | 23 qtrs — |
| 25 | BANK OF AMERICA CORP /DE/ | 495.9K +315.4K (+174.8%) | 2.64M +1.9M (+236.7%) | 1.17% +0.746 pp | 0.00% +0.000 pp | USD5.19 +2.7% | 9 qtrs — |
| 26 | BURKEHILL GLOBAL MANAGEMENT, LP | 450.0K +450.0K (+100.0%) | 2.40M +2.4M (+100.0%) | 1.06% +1.065 pp | 0.16% +0.158 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 27 | SUPERSTRING CAPITAL MANAGEMENT LP | 360.0K +— (+0.0%) | 1.92M +352.8K (+22.5%) | 0.85% +0.000 pp | 1.03% -0.516 pp | USD5.28 +0.9% | 5 qtrs — |
| 28 | ALYESKA INVESTMENT GROUP, L.P. | 350.0K +350.0K (+100.0%) | 1.87M +1.9M (+100.0%) | 0.83% +0.828 pp | 0.01% +0.005 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 29 | ASSENAGON ASSET MANAGEMENT S.A. | 308.3K +912.0 (+0.3%) | 1.64M +306.1K (+22.9%) | 0.73% +0.002 pp | 0.00% +0.000 pp | USD4.35 +22.5% | 2 qtrs — |
| 30 | RENAISSANCE TECHNOLOGIES LLC | 266.8K -47.5K (-15.1%) | 1.42M +54.9K (+4.0%) | 0.63% -0.112 pp | 0.00% +0.000 pp | USD3.46 +54.0% | 23 qtrs — |
| 31 | NORTHERN TRUST CORP | 240.8K +6.4K (+2.7%) | 1.28M +263.8K (+25.9%) | 0.57% +0.015 pp | 0.00% +0.000 pp | USD4.60 +15.9% | 23 qtrs — |
| 32 | CIBC WORLD MARKET INC. | 228.9K -46.1K (-16.8%) | 1.22M +23.8K (+2.0%) | 0.54% -0.109 pp | 0.00% 0.000 pp | USD4.02 +32.6% | 7 qtrs — |
| 33 | DIMENSIONAL FUND ADVISORS LP | 227.2K +179.4K (+376.1%) | 1.21M +1.0M (+482.7%) | 0.54% +0.425 pp | 0.00% +0.000 pp | USD5.11 +4.3% | 5 qtrs — |
| 34 | OPPENHEIMER & CO INC | 223.8K +16.8K (+8.1%) | 1.19M +292.3K (+32.5%) | 0.53% +0.040 pp | 0.02% +0.006 pp | USD2.82 +89.0% | 8 qtrs — |
| 35 | MORGAN STANLEY | 175.3K +66.8K (+61.5%) | 934.5K +462.3K (+97.9%) | 0.41% +0.158 pp | 0.00% +0.000 pp | USD4.62 +15.4% | 5 qtrs — |
| 36 | JANE STREET GROUP, LLC | 156.1K +110.9K (+245.1%) | 832.2K +635.4K (+322.8%) | 0.37% +0.262 pp | 0.00% +0.000 pp | USD5.10 +4.5% | 7 qtrs — |
| 37 | AMERIPRISE FINANCIAL INC | 154.0K +154.0K (+100.0%) | 820.7K +820.7K (+100.0%) | 0.36% +0.364 pp | 0.00% +0.000 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 38 | WALLEYE CAPITAL LLC | 145.9K +145.9K (+100.0%) | 777.5K +777.5K (+100.0%) | 0.35% +0.345 pp | 0.00% +0.002 pp | USD5.33 +0.0% | 5 qtrs — |
| 39 | MONASHEE INVESTMENT MANAGEMENT LLC | 125.0K +125.0K (+100.0%) | 666.3K +666.3K (+100.0%) | 0.30% +0.296 pp | 0.38% +0.375 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 40 | XTX TOPCO LTD | 115.4K +115.4K (+100.0%) | 614.9K +614.9K (+100.0%) | 0.27% +0.273 pp | 0.02% +0.016 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 41 | QUBE RESEARCH & TECHNOLOGIES LTD | 114.3K +114.3K (+100.0%) | 609.4K +609.4K (+100.0%) | 0.27% +0.271 pp | 0.00% +0.001 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 42 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 106.8K +25.6K (+31.6%) | 569.5K +216.3K (+61.2%) | 0.25% +0.061 pp | 0.00% +0.000 pp | USD5.13 +3.9% | 10 qtrs — |
| 43 | EAM INVESTORS, LLC | 103.6K +103.6K (+100.0%) | 552.2K +552.2K (+100.0%) | 0.25% +0.245 pp | 0.06% +0.062 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 44 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 102.5K +6.7K (+7.0%) | 546.3K +129.7K (+31.1%) | 0.24% +0.016 pp | 0.00% +0.000 pp | USD3.36 +58.6% | 4 qtrs — |
| 45 | BANK OF NEW YORK MELLON CORP | 93.5K -3.5K (-3.6%) | 498.5K +76.6K (+18.1%) | 0.22% -0.008 pp | 0.00% +0.000 pp | USD6.54 -18.5% | 21 qtrs — |
| 46 | NUVEEN, LLC | 86.5K -197.0K (-69.5%) | 461.1K -772.1K (-62.6%) | 0.20% -0.466 pp | 0.00% 0.000 pp | USD3.88 +37.4% | 3 qtrs — |
| 47 | MAREX GROUP PLC | 85.3K +63.0K (+283.1%) | 454.4K +357.6K (+369.5%) | 0.20% +0.149 pp | 0.00% +0.002 pp | USD5.07 +5.1% | 2 qtrs — |
| 48 | VIRTU FINANCIAL LLC | 69.0K +69.0K (+100.0%) | 368.0K +368.0K (+100.0%) | 0.16% +0.163 pp | 0.01% +0.014 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 49 | AMERICAN CENTURY COMPANIES INC | 64.2K +2.6K (+4.2%) | 342.0K +74.2K (+27.7%) | 0.15% +0.006 pp | 0.00% +0.000 pp | USD3.82 +39.5% | 4 qtrs — |
| 50 | GOLDMAN SACHS GROUP INC | 63.5K +49.9K (+366.6%) | 338.4K +279.2K (+471.7%) | 0.15% +0.118 pp | 0.00% +0.000 pp | USD5.32 +0.2% | 5 qtrs — |
| 51 | SEI INVESTMENTS CO | 63.1K +63.1K (+100.0%) | 336.2K +336.2K (+100.0%) | 0.15% +0.149 pp | 0.00% +0.000 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 52 | BARCLAYS PLC | 55.1K +9.5K (+21.0%) | 293.5K +95.4K (+48.2%) | 0.13% +0.023 pp | 0.00% +0.000 pp | USD5.29 +0.8% | 5 qtrs — |
| 53 | GSA CAPITAL PARTNERS LLP | 52.3K -49.2K (-48.4%) | 279.0K -162.0K (-36.7%) | 0.12% -0.116 pp | 0.02% -0.013 pp | USD4.16 +28.1% | 5 qtrs — |
| 54 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 44.8K +— (+0.0%) | 238.9K +43.9K (+22.5%) | 0.11% +0.000 pp | 0.01% +0.001 pp | USD3.82 +39.5% | 18 qtrs — |
| 55 | PANAGORA ASSET MANAGEMENT INC | 43.8K +43.8K (+100.0%) | 233.4K +233.4K (+100.0%) | 0.10% +0.104 pp | 0.00% +0.001 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 56 | ALPS ADVISORS INC | 42.4K +42.4K (+100.0%) | 225.9K +225.9K (+100.0%) | 0.10% +0.100 pp | 0.00% +0.001 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 57 | TRUIST FINANCIAL CORP | 40.0K +— (+0.0%) | 213.2K +39.2K (+22.5%) | 0.09% +0.000 pp | 0.00% +0.000 pp | USD2.99 +78.3% | 8 qtrs — |
| 58 | WELLS FARGO & COMPANY/MN | 39.8K +15.0K (+60.7%) | 212.1K +104.4K (+96.9%) | 0.09% +0.036 pp | 0.00% +0.000 pp | USD4.03 +32.3% | 3 qtrs — |
| 59 | HRT FINANCIAL LP | 36.3K +36.3K (+100.0%) | 193.0K +193.0K (+100.0%) | 0.09% +0.086 pp | 0.00% +0.001 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 60 | LPL FINANCIAL LLC | 36.1K +— (+0.0%) | 192.1K +35.3K (+22.5%) | 0.09% +0.000 pp | 0.00% +0.000 pp | USD3.05 +74.8% | 12 qtrs — |
| 61 | LONGAEVA PARTNERS L.P. | 33.9K +33.9K (+100.0%) | 180.5K +180.5K (+100.0%) | 0.08% +0.080 pp | 0.02% +0.015 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 62 | TWO SIGMA INVESTMENTS, LP | 32.7K +13.1K (+67.0%) | 174.1K +89.0K (+104.6%) | 0.08% +0.031 pp | 0.00% +0.000 pp | USD4.29 +24.2% | 22 qtrs — |
| 63 | POINT72 ASSET MANAGEMENT, L.P. | 28.1K +28.1K (+100.0%) | 149.8K +149.8K (+100.0%) | 0.07% +0.067 pp | 0.00% +0.000 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 64 | RHUMBLINE ADVISERS | 26.9K -7.3K (-21.3%) | 143.2K -5.3K (-3.6%) | 0.06% -0.017 pp | 0.00% +0.000 pp | USD3.13 +70.3% | 3 qtrs — |
| 65 | DEUTSCHE BANK AG\ | 25.1K +25.1K (+100.0%) | 133.8K +133.8K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD5.33 +0.0% | 3 qtrs — |
| 66 | BAILARD, INC. | 24.4K -12.3K (-33.4%) | 130.1K -29.4K (-18.4%) | 0.06% -0.029 pp | 0.00% -0.001 pp | USD5.10 +4.5% | 5 qtrs — |
| 67 | QUADRATURE CAPITAL LTD | 24.2K +6.8K (+39.4%) | 128.9K +53.8K (+71.6%) | 0.06% +0.016 pp | 0.00% +0.000 pp | USD3.99 +33.6% | 3 qtrs — |
| 68 | ALMANACK INVESTMENT PARTNERS, LLC. | 23.8K +10.3K (+76.2%) | 126.8K +68.1K (+115.9%) | 0.06% +0.024 pp | 0.02% +0.013 pp | USD4.77 +11.7% | 2 qtrs — |
| 69 | ENGINEERS GATE MANAGER LP | 21.9K +21.9K (+100.0%) | 116.7K +116.7K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.001 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 70 | PRICE T ROWE ASSOCIATES INC /MD/ | 20.7K +4.4K (+26.8%) | 111.0K +39.0K (+54.2%) | 0.05% +0.010 pp | 0.00% +0.000 pp | USD3.52 +51.4% | 3 qtrs — |
| 71 | CAMPBELL & CO INVESTMENT ADVISER LLC | 20.6K +20.6K (+100.0%) | 109.5K +109.5K (+100.0%) | 0.05% +0.049 pp | 0.01% +0.005 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 72 | GROUP ONE TRADING, L.P. | 18.4K +15.5K (+534.5%) | 98.1K +85.5K (+677.4%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD5.18 +2.9% | 2 qtrs — |
| 73 | INVESCO LTD. | 17.5K -7.7K (-30.4%) | 93.4K -16.1K (-14.7%) | 0.04% -0.018 pp | 0.00% +0.000 pp | USD3.09 +72.5% | 3 qtrs — |
| 74 | SCIENTECH RESEARCH LLC | 17.2K +17.2K (+100.0%) | 91.8K +91.8K (+100.0%) | 0.04% +0.041 pp | 0.06% +0.058 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 75 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 16.4K +1.5K (+10.1%) | 87.2K +22.6K (+34.9%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD3.24 +64.5% | 3 qtrs — |
| 76 | NEW YORK STATE COMMON RETIREMENT FUND | 15.0K -4.7K (-23.9%) | 80.0K -5.7K (-6.7%) | 0.04% -0.011 pp | 0.00% +0.000 pp | USD3.03 +75.9% | 3 qtrs — |
| 77 | CITIGROUP INC | 14.7K +14.3K (+3,788.9%) | 78.4K +76.7K (+4,665.9%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD5.29 +0.8% | 5 qtrs — |
| 78 | AQR CAPITAL MANAGEMENT LLC | 14.7K +14.7K (+100.0%) | 78.3K +78.3K (+100.0%) | 0.03% +0.035 pp | 0.00% +0.000 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 79 | JPMORGAN CHASE & CO | 14.6K +247.0 (+1.7%) | 77.7K +15.4K (+24.6%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD3.07 +73.6% | 3 qtrs — |
| 80 | INTECH INVESTMENT MANAGEMENT LLC | 13.8K -2.1K (-13.1%) | 73.7K +4.5K (+6.5%) | 0.03% -0.005 pp | 0.00% +0.000 pp | USD3.03 +75.9% | 3 qtrs — |
| 81 | SQUAREPOINT OPS LLC | 12.7K +307.0 (+2.5%) | 67.6K +13.8K (+25.6%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD4.19 +27.2% | 5 qtrs — |
| 82 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 11.1K +11.1K (+100.0%) | 59.1K +59.1K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.000 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 83 | COMMONWEALTH EQUITY SERVICES, LLC | 11.0K +1.0K (+10.0%) | 58.6K +14.6K (+33.3%) | 0.03% +0.002 pp | 0.00% +0.000 pp | USD4.44 +20.0% | 7 qtrs — |
| 84 | AXQ CAPITAL, LP | 10.8K +10.8K (+100.0%) | 57.6K +57.6K (+100.0%) | 0.03% +0.026 pp | 0.01% +0.013 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 85 | PERSISTENT ASSET PARTNERS LTD | 10.7K +10.7K (+100.0%) | 57.2K +57.2K (+100.0%) | 0.03% +0.025 pp | 0.03% +0.026 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 86 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 9.9K +— (+0.0%) | 52.9K +9.7K (+22.5%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD3.03 +75.9% | 3 qtrs — |
| 87 | BNP PARIBAS ARBITRAGE, SNC | 7.6K -42.8K (-84.9%) | 40.6K -178.9K (-81.5%) | 0.02% -0.101 pp | 0.00% 0.000 pp | USD5.24 +1.7% | 5 qtrs — |
| 88 | ROYAL BANK OF CANADA | 4.5K +180.0 (+4.2%) | 25.0K +7.0K (+38.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.14 +69.7% | 11 qtrs — |
| 89 | METLIFE INVESTMENT MANAGEMENT, LLC | 4.4K +4.4K (+100.0%) | 23.4K +23.4K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD5.33 +0.0% | 1 qtrs NEW |
| 90 | AMERITAS INVESTMENT PARTNERS, INC. | 3.3K +— (+0.0%) | 17.6K +3.2K (+22.5%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.03 +75.9% | 3 qtrs — |
| 91 | LEGAL & GENERAL GROUP PLC | 2.9K +— (+0.0%) | 15.7K +2.9K (+22.5%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.03 +75.9% | 3 qtrs — |
| 92 | RUSSELL INVESTMENTS GROUP, LTD. | 2.7K +— (+0.0%) | 14.3K +2.6K (+22.5%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD4.35 +22.5% | 2 qtrs — |
| 93 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2.2K +152.0 (+7.5%) | 11.6K +2.8K (+31.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.19 +67.1% | 3 qtrs — |
| 94 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.1K -3.5K (-62.9%) | 11.0K -13.3K (-54.5%) | 0.00% -0.008 pp | 0.00% 0.000 pp | USD3.29 +62.0% | 11 qtrs — |
| 95 | STERLING CAPITAL MANAGEMENT LLC | 2.0K -197.0 (-8.8%) | 10.8K +1.1K (+11.7%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.83 +39.2% | 3 qtrs — |
| 96 | AMALGAMATED BANK | 1.1K +5.0 (+0.5%) | 6.0K +1.0K (+20.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.04 +75.3% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 49 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ALPS Medical Breakthroughs ETF SBIO | 0.12% | 265.1K | 0.50% |
| 2 | Vanguard Global Momentum Factor ETF VMO.TO | 0.07% | 236.0K | 0.38% |
| 3 | iShares Micro-Cap ETF IWC | 0.05% | 759.6K | 0.60% |
| 4 | Vanguard U.S. Momentum Factor ETF VFMO | 0.05% | 775.2K | 0.13% |
| 5 | iShares Russell 2000 Value ETF IWN | 0.01% | 2.03M | 0.24% |
| 6 | Vanguard Russell 2000 Value ETF VTWV | 0.01% | 182.0K | 0.06% |
| 7 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 410.3K | 0.25% |
| 8 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.01% | 536.5K | 0.30% |
| 9 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 223.4K | 0.30% |
| 10 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 4.1K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
23.7K
Cash buys
—
Cash sales
2.00
Net activity
-23,732
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-08 | Zummo Jacqueline | Officer | S-Sale | D | Common Stock | 1,134 | 5.40 | 6.1K | 94,827 | D | ↗ |
| 2026-04-01 | Zummo Jacqueline | Officer | S-Sale | D | Common Stock | 22,598 | 5.26 | 118.9K | 95,961 | D | ↗ |
| 2026-01-26 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 3,724 | 6.67 | 24.8K | 118,559 | D | ↗ |
| 2026-01-26 | Shefferman Jesse | Director / Officer | F-InKind | D | Common Stock | 8,732 | 6.67 | 58.2K | 1,021,832 | D | ↗ |
| 2026-01-26 | Fry Hannah | Officer | F-InKind | D | Common Stock | 1,457 | 6.67 | 9.7K | 42,723 | D | ↗ |
| 2026-01-26 | Fabbio Patrick | Officer | F-InKind | D | Common Stock | 3,261 | 6.67 | 21.8K | 64,115 | D | ↗ |
| 2026-01-20 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 6,578 | 5.60 | 36.8K | 122,283 | D | ↗ |
| 2026-01-20 | Shefferman Jesse | Director / Officer | F-InKind | D | Common Stock | 16,322 | 5.60 | 91.4K | 1,030,564 | D | ↗ |
| 2026-01-20 | Fry Hannah | Officer | F-InKind | D | Common Stock | 2,132 | 5.60 | 11.9K | 44,180 | D | ↗ |
| 2026-01-20 | Fabbio Patrick | Officer | F-InKind | D | Common Stock | 3,063 | 5.60 | 17.2K | 67,376 | D | ↗ |
| 2026-01-16 | Zummo Jacqueline | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 128,861 | D | ↗ |
| 2026-01-16 | Shefferman Jesse | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 524,000 | 5.01 | 2.63M | 524,000 | D | ↗ |
| 2026-01-16 | Nicacio Leonardo Viana | Officer | A-Award | A | Stock Option (Right to Buy) | 158,000 | 5.01 | 791.6K | 158,000 | D | ↗ |
| 2026-01-16 | Fry Hannah | Officer | A-Award | A | Common Stock | 9,500 | 0.00 | — | 46,312 | D | ↗ |
| 2026-01-16 | Fabbio Patrick | Officer | A-Award | A | Common Stock | 28,000 | 0.00 | — | 70,439 | D | ↗ |
| 2026-01-16 | CONKLING WILLIAM | Officer | A-Award | A | Common Stock | 26,000 | 0.00 | — | 76,000 | D | ↗ |
| 2025-06-27 | Shefferman Jesse | Director / Officer | G-Gift | D | Common Stock | 3,367 | 0.00 | — | 959,886 | D | ↗ |
| 2025-06-26 | Shefferman Jesse | Director / Officer | G-Gift | D | Common Stock | 3,400 | 0.00 | — | 973,453 | D | ↗ |
| 2025-06-24 | Shefferman Jesse | Director / Officer | G-Gift | D | Common Stock | 300,000 | 0.00 | — | 659,886 | D | ↗ |
| 2025-06-12 | Solomon Michael Edward | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.26 | 78.2K | 24,000 | D | ↗ |
| 2025-06-12 | Smith Cynthia | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.26 | 78.2K | 24,000 | D | ↗ |
| 2025-06-12 | SARGEN GREGORY | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.26 | 78.2K | 24,000 | D | ↗ |
| 2025-06-12 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.26 | 78.2K | 24,000 | D | ↗ |
| 2025-06-12 | Huang Jane | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.26 | 78.2K | 24,000 | D | ↗ |
| 2025-06-12 | GARCEAU ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.26 | 78.2K | 24,000 | D | ↗ |
| 2025-06-12 | Flannelly Barry P | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.26 | 78.2K | 24,000 | D | ↗ |
| 2025-06-12 | BESHAR LUKE M | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.26 | 78.2K | 24,000 | D | ↗ |
| 2025-06-02 | CONKLING WILLIAM | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-05-14 | Levy Richard S | Director | P-Purchase | A | Common Stock | 20,000 | 3.19 | 63.8K | 51,000 | D | ↗ |
| 2025-04-15 | Nicacio Leonardo Viana | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 4.17 | 625.5K | 150,000 | D | ↗ |
| 2025-03-26 | Zummo Jacqueline | Officer | S-Sale | D | Common Stock | 21,224 | 4.53 | 96.1K | 98,861 | D | ↗ |
| 2025-01-24 | Zummo Jacqueline | Officer | A-Award | A | Stock Option (Right to Buy) | 146,000 | 4.53 | 661.4K | 146,000 | D | ↗ |
| 2025-01-24 | Shefferman Jesse | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 387,000 | 4.53 | 1.75M | 387,000 | D | ↗ |
| 2025-01-24 | Fry Hannah | Officer | A-Award | A | Common Stock | 9,500 | 0.00 | — | 38,942 | D | ↗ |
| 2025-01-24 | Fabbio Patrick | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 4.53 | 634.2K | 140,000 | D | ↗ |
| 2025-01-21 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 6,554 | 4.76 | 31.2K | 95,585 | D | ↗ |
| 2025-01-21 | Shefferman Jesse | Director / Officer | F-InKind | D | Common Stock | 15,469 | 4.76 | 73.6K | 913,553 | D | ↗ |
| 2025-01-21 | Fry Hannah | Officer | F-InKind | D | Common Stock | 2,130 | 4.76 | 10.1K | 27,312 | D | ↗ |
| 2025-01-21 | Fabbio Patrick | Officer | F-InKind | D | Common Stock | 3,061 | 4.76 | 14.6K | 18,939 | D | ↗ |
| 2025-01-03 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 2,157 | 6.14 | 13.2K | 102,139 | D | ↗ |
| 2025-01-03 | Shefferman Jesse | Director / Officer | F-InKind | D | Common Stock | 6,479 | 6.14 | 39.8K | 929,022 | D | ↗ |
| 2025-01-03 | Fry Hannah | Officer | F-InKind | D | Common Stock | 394 | 6.14 | 2.4K | 29,442 | D | ↗ |
| 2024-09-12 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 119,801 | 1.71 | 204.7K | 1,944,134 | — | ↗ |
| 2024-09-11 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 31,000 | 1.71 | 53.1K | 2,063,935 | — | ↗ |
| 2024-09-10 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 24,000 | 1.77 | 42.5K | 2,094,935 | — | ↗ |
| 2024-09-09 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 34,592 | 1.89 | 65.5K | 2,118,935 | — | ↗ |
| 2024-08-28 | Shefferman Jesse | Director / Officer | G-Gift | D | Common Stock | 3,300 | 0.00 | — | 935,501 | — | ↗ |
| 2024-07-16 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 3,500 | 2.44 | 8.5K | 56,500 | — | ↗ |
| 2024-07-11 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 15,000 | 2.40 | 36.1K | 60,000 | — | ↗ |
| 2024-07-10 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 13,061 | 2.31 | 30.1K | 2,194,416 | — | ↗ |
| 2024-07-09 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 5,997 | 2.21 | 13.3K | 2,207,477 | — | ↗ |
| 2024-07-01 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 5,788 | 2.12 | 12.3K | 2,213,474 | — | ↗ |
| 2024-06-28 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 12,994 | 2.07 | 27.0K | 2,219,262 | — | ↗ |
| 2024-06-27 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 34,103 | 2.26 | 77.0K | 2,232,256 | — | ↗ |
| 2024-06-25 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 6,500 | 2.26 | 14.7K | 2,266,359 | — | ↗ |
| 2024-06-07 | Solomon Michael Edward | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.67 | 26.7K | 10,000 | — | ↗ |
| 2024-06-07 | Smith Cynthia | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.67 | 26.7K | 10,000 | — | ↗ |
| 2024-06-07 | SARGEN GREGORY | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.67 | 26.7K | 10,000 | — | ↗ |
| 2024-06-07 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.67 | 26.7K | 10,000 | — | ↗ |
| 2024-06-07 | Huang Jane | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.67 | 26.7K | 10,000 | — | ↗ |
| 2024-06-07 | GARCEAU ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.67 | 26.7K | 10,000 | — | ↗ |
| 2024-06-07 | Flannelly Barry P | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.67 | 26.7K | 10,000 | — | ↗ |
| 2024-06-07 | BESHAR LUKE M | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.67 | 26.7K | 10,000 | — | ↗ |
| 2024-05-31 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 5,824 | 2.90 | 16.9K | 108,696 | — | ↗ |
| 2024-05-30 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 9,230 | 2.94 | 27.1K | 114,520 | — | ↗ |
| 2024-05-22 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 9,300 | 3.02 | 28.1K | 2,272,859 | — | ↗ |
| 2024-05-21 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 31,200 | 3.06 | 95.3K | 2,282,159 | — | ↗ |
| 2024-05-17 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 2,750 | 3.33 | 9.2K | 127,250 | — | ↗ |
| 2024-05-10 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 151,700 | 3.11 | 472.4K | 2,380,294 | — | ↗ |
| 2024-05-09 | Opaleye Management Inc. | 10% Owner | S-Sale | D | Common Stock, par value $0.001 per share | 30,600 | 3.09 | 94.5K | 2,531,994 | — | ↗ |
| 2024-01-19 | Zummo Jacqueline | Officer | A-Award | A | Common Stock | 23,000 | 0.00 | — | 107,345 | — | ↗ |
| 2024-01-19 | Shefferman Jesse | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 357,000 | 1.91 | 681.9K | 357,000 | — | ↗ |
| 2024-01-19 | Fry Hannah | Officer | F-InKind | D | Common Stock | 904 | 1.91 | 1.7K | 29,836 | — | ↗ |
| 2024-01-19 | Fabbio Patrick | Officer | A-Award | A | Common Stock | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2024-01-19 | Bandari Jathin | Officer | F-InKind | D | Common Stock | 2,879 | 1.91 | 5.5K | 56,704 | — | ↗ |
| 2024-01-10 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 5,229 | 2.39 | 12.5K | 84,345 | — | ↗ |
| 2024-01-10 | Shefferman Jesse | Director / Officer | F-InKind | D | Common Stock | 5,746 | 2.39 | 13.7K | 892,867 | — | ↗ |
| 2024-01-10 | Bandari Jathin | Officer | F-InKind | D | Common Stock | 1,877 | 2.39 | 4.5K | 36,583 | — | ↗ |
| 2024-01-03 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 1,899 | 2.17 | 4.1K | 89,574 | — | ↗ |
| 2024-01-03 | Shefferman Jesse | Director / Officer | F-InKind | D | Common Stock | 5,840 | 2.17 | 12.7K | 898,613 | — | ↗ |
| 2024-01-03 | Fry Hannah | Officer | F-InKind | D | Common Stock | 324 | 2.17 | 703.08 | 22,740 | — | ↗ |
| 2023-07-17 | Fry Hannah | Officer | F-InKind | D | Common Stock | 10,075 | 2.56 | 25.8K | 23,064 | — | ↗ |
| 2023-07-03 | Bandari Jathin | Officer | F-InKind | D | Common Stock | 682 | 2.46 | 1.7K | 38,460 | — | ↗ |
| 2023-06-27 | Shefferman Jesse | Director / Officer | G-Gift | D | Common Stock | 7,420 | 0.00 | — | 904,453 | — | ↗ |
| 2023-06-23 | Shefferman Jesse | Director / Officer | G-Gift | D | Common Stock | 1,890 | 0.00 | — | 911,873 | — | ↗ |
| 2023-06-07 | Solomon Michael Edward | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2023-06-07 | Smith Cynthia | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2023-06-07 | SARGEN GREGORY | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2023-06-07 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2023-06-07 | Huang Jane | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2023-06-07 | GARCEAU ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2023-06-07 | Flannelly Barry P | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2023-06-07 | BESHAR LUKE M | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.85 | 28.5K | 10,000 | — | ↗ |
| 2023-01-30 | Fabbio Patrick | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 0.00 | — | 300,000 | — | ↗ |
| 2023-01-19 | Zummo Jacqueline | Officer | A-Award | A | Stock Option (Right to Buy) | 119,300 | 0.00 | — | 119,300 | — | ↗ |
| 2023-01-19 | Shefferman Jesse | Officer | A-Award | A | Stock Option (Right to Buy) | 307,500 | 0.00 | — | 307,500 | — | ↗ |
| 2023-01-19 | Fry Hannah | Officer | A-Award | A | Common Stock | 5,900 | 0.00 | — | 33,139 | — | ↗ |
| 2023-01-19 | Bandari Jathin | Officer | A-Award | A | Common Stock | 20,700 | 0.00 | — | 39,142 | — | ↗ |
| 2023-01-10 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 5,225 | 3.00 | 15.7K | 71,573 | — | ↗ |
| 2023-01-10 | Shefferman Jesse | Officer | F-InKind | D | Common Stock | 5,855 | 3.00 | 17.6K | 866,982 | — | ↗ |
| 2023-01-10 | Bandari Jathin | Officer | F-InKind | D | Common Stock | 1,876 | 3.00 | 5.6K | 18,442 | — | ↗ |
| 2023-01-03 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 2,159 | 2.80 | 6.0K | 76,798 | — | ↗ |
| 2023-01-03 | Shefferman Jesse | Officer | F-InKind | D | Common Stock | 6,604 | 2.80 | 18.5K | 872,837 | — | ↗ |
| 2023-01-03 | Fry Hannah | Officer | F-InKind | D | Common Stock | 361 | 2.80 | 1.0K | 27,239 | — | ↗ |
| 2022-12-31 | Shefferman Jesse | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-30 | Opaleye Management Inc. | Director | S-Sale | A | Common Stock, par value $0.001 per share | 13,173 | 2.71 | 35.7K | 2,562,594 | — | ↗ |
| 2022-09-15 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 2,300 | 3.80 | 8.7K | 132,300 | — | ↗ |
| 2022-09-14 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 14,100 | 3.98 | 56.1K | 2,570,777 | — | ↗ |
| 2022-08-11 | Shefferman Jesse | Officer | P-Purchase | A | Common Stock | 9,065 | 3.84 | 34.8K | 879,441 | — | ↗ |
| 2022-07-16 | Fry Hannah | Officer | — | D | Stock Option (right to buy) | 500 | 26.32 | 13.2K | 0 | — | ↗ |
| 2022-07-15 | Davis Blaine | Officer | F-InKind | D | Common Stock | 5,081 | 3.13 | 15.9K | 20,662 | — | ↗ |
| 2022-07-01 | Bandari Jathin | Officer | F-InKind | D | Common Stock | 682 | 3.22 | 2.2K | 20,318 | — | ↗ |
| 2022-06-30 | BESHAR LUKE M | Director | P-Purchase | A | Common Stock | 10,000 | 3.10 | 31.0K | 198,000 | — | ↗ |
| 2022-06-08 | Solomon Michael Edward | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.50 | 35.0K | 10,000 | — | ↗ |
| 2022-06-08 | Smith Cynthia | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-08 | SARGEN GREGORY | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-08 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.50 | 35.0K | 10,000 | — | ↗ |
| 2022-06-08 | Huang Jane | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-08 | GARCEAU ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.50 | 35.0K | 10,000 | — | ↗ |
| 2022-06-08 | Flannelly Barry P | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2022-06-08 | BESHAR LUKE M | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 3.50 | 35.0K | 10,000 | — | ↗ |
| 2022-04-08 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 2,469 | 4.80 | 11.8K | 127,500 | — | ↗ |
| 2022-04-07 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 1,345 | 4.74 | 6.4K | 2,551,345 | — | ↗ |
| 2022-03-14 | BESHAR LUKE M | Director | P-Purchase | A | Common Stock | 10,000 | 4.25 | 42.5K | 188,000 | — | ↗ |
| 2022-03-10 | BESHAR LUKE M | Director | P-Purchase | A | Common Stock | 10,000 | 4.46 | 44.6K | 178,000 | — | ↗ |
| 2022-01-28 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 20,000 | 4.96 | 99.3K | 2,550,000 | — | ↗ |
| 2022-01-10 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 4,603 | 6.27 | 28.9K | 78,957 | — | ↗ |
| 2022-01-10 | Shefferman Jesse | Director / Officer | F-InKind | D | Common Stock | 5,080 | 6.27 | 31.9K | 872,425 | — | ↗ |
| 2022-01-10 | Bandari Jathin | Officer | — | D | Common Stock | 0 | 0.00 | — | 7,500 | — | ↗ |
| 2022-01-03 | Zummo Jacqueline | Officer | A-Award | A | Common Stock | 14,100 | 0.00 | — | 83,560 | — | ↗ |
| 2022-01-03 | Shefferman Jesse | Director / Officer | A-Award | A | Common Stock | 42,300 | 0.00 | — | 877,505 | — | ↗ |
| 2022-01-03 | Davis Blaine | Officer | A-Award | A | Stock Option (Right to Buy) | 84,800 | 6.90 | 585.1K | 84,800 | — | ↗ |
| 2021-12-31 | Shefferman Jesse | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-29 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 4,500 | 6.98 | 31.4K | 120,000 | — | ↗ |
| 2021-12-28 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 1,591 | 6.36 | 10.1K | 2,530,000 | — | ↗ |
| 2021-12-27 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 31,700 | 6.53 | 207.1K | 2,528,409 | — | ↗ |
| 2021-12-23 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 800 | 6.60 | 5.3K | 105,000 | — | ↗ |
| 2021-12-20 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 703 | 6.49 | 4.6K | 2,496,209 | — | ↗ |
| 2021-12-17 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 2,300 | 6.60 | 15.2K | 2,495,506 | — | ↗ |
| 2021-12-16 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 6,500 | 6.41 | 41.7K | 2,493,206 | — | ↗ |
| 2021-11-18 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 14,206 | 6.98 | 99.2K | 2,486,706 | — | ↗ |
| 2021-11-17 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 8,028 | 6.98 | 56.0K | 2,472,500 | — | ↗ |
| 2021-11-04 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 6,000 | 6.50 | 39.0K | 2,464,472 | — | ↗ |
| 2021-06-10 | Olivo Martin Sebastian | Officer | P-Purchase | A | Common Stock | 4,934 | 10.13 | 50.0K | 14,344 | — | ↗ |
| 2021-06-09 | Solomon Michael Edward | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.51 | 105.1K | 10,000 | — | ↗ |
| 2021-06-09 | Smith Cynthia | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.51 | 105.1K | 10,000 | — | ↗ |
| 2021-06-09 | SARGEN GREGORY | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.51 | 105.1K | 10,000 | — | ↗ |
| 2021-06-09 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.51 | 105.1K | 10,000 | — | ↗ |
| 2021-06-09 | Huang Jane | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 10.51 | 210.2K | 20,000 | — | ↗ |
| 2021-06-09 | GARCEAU ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.51 | 105.1K | 10,000 | — | ↗ |
| 2021-06-09 | Flannelly Barry P | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.51 | 105.1K | 10,000 | — | ↗ |
| 2021-06-09 | BESHAR LUKE M | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.51 | 105.1K | 10,000 | — | ↗ |
| 2021-04-19 | Olivo Martin Sebastian | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 15.30 | 1.84M | 120,000 | — | ↗ |
| 2021-01-29 | Smith Cynthia | Director | A-Award | A | Stock Option (Right to Buy) | 3,750 | 17.98 | 67.4K | 21,750 | — | ↗ |
| 2021-01-19 | Zummo Jacqueline | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 19.82 | 1.49M | 75,000 | — | ↗ |
| 2021-01-19 | Shefferman Jesse | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 202,000 | 19.82 | 4.00M | 202,000 | — | ↗ |
| 2021-01-19 | Davis Blaine | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 19.82 | 1.49M | 75,000 | — | ↗ |
| 2021-01-11 | Zummo Jacqueline | Officer | F-InKind | D | Common Stock | 4,653 | 21.16 | 98.5K | 69,460 | — | ↗ |
| 2021-01-11 | Shefferman Jesse | Director / Officer | F-InKind | D | Common Stock | 5,069 | 21.16 | 107.3K | 835,205 | — | ↗ |
| 2020-09-30 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 50,000 | 16.00 | 800.0K | 2,458,472 | — | ↗ |
| 2020-09-24 | Opaleye Management Inc. | 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 100,000 | 16.87 | 1.69M | 100,000 | — | ↗ |
| 2020-09-22 | Davis Blaine | Officer | P-Purchase | A | Common Stock | 1,481 | 16.91 | 25.0K | 1,481 | — | ↗ |
| 2020-09-14 | Marshall Randall | — | S-Sale | D | Common Stock | 2,080 | 19.26 | 40.1K | 586,074 | — | ↗ |
| 2020-09-10 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 239 | 18.00 | 4.3K | 588,154 | — | ↗ |
| 2020-09-09 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 5,309 | 18.10 | 96.1K | 593,306 | — | ↗ |
| 2020-09-08 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 3,108 | 18.94 | 58.9K | 598,615 | — | ↗ |
| 2020-09-03 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 52 | 20.19 | 1.0K | 601,723 | — | ↗ |
| 2020-09-02 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 207 | 20.68 | 4.3K | 601,775 | — | ↗ |
| 2020-08-28 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 771 | 22.09 | 17.0K | 601,982 | — | ↗ |
| 2020-08-27 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 616 | 22.37 | 13.8K | 602,753 | — | ↗ |
| 2020-08-26 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 1,418 | 22.40 | 31.8K | 603,369 | — | ↗ |
| 2020-08-25 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 2,461 | 22.73 | 55.9K | 604,787 | — | ↗ |
| 2020-08-24 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 974 | 23.16 | 22.6K | 607,248 | — | ↗ |
| 2020-08-20 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 510 | 24.18 | 12.3K | 608,222 | — | ↗ |
| 2020-08-18 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 200 | 25.19 | 5.0K | 608,732 | — | ↗ |
| 2020-08-17 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 1,548 | 25.11 | 38.9K | 608,932 | — | ↗ |
| 2020-08-14 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 700 | 25.09 | 17.6K | 610,480 | — | ↗ |
| 2020-07-30 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 1,317 | 26.14 | 34.4K | 611,180 | — | ↗ |
| 2020-07-29 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 1,816 | 26.03 | 47.3K | 613,197 | — | ↗ |
| 2020-07-28 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 3,493 | 31.53 | 110.1K | 618,463 | — | ↗ |
| 2020-07-27 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 338 | 26.08 | 8.8K | 640,610 | — | ↗ |
| 2020-07-24 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 300 | 26.00 | 7.8K | 640,948 | — | ↗ |
| 2020-07-23 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 1,950 | 26.58 | 51.8K | 641,341 | — | ↗ |
| 2020-07-23 | Flannelly Barry P | Director | A-Award | A | Stock Option (Right to Buy) | 8,250 | 26.70 | 220.3K | 26,250 | — | ↗ |
| 2020-07-22 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 1,297 | 26.69 | 34.6K | 643,366 | — | ↗ |
| 2020-07-21 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 223 | 26.56 | 5.9K | 644,663 | — | ↗ |
| 2020-07-20 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 2,257 | 26.70 | 60.3K | 645,358 | — | ↗ |
| 2020-07-17 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 1,601 | 26.66 | 42.7K | 647,615 | — | ↗ |
| 2020-07-13 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 2,145 | 27.13 | 58.2K | 649,216 | — | ↗ |
| 2020-07-10 | Shefferman Jesse | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 111,250 | 27.42 | 3.05M | 111,250 | — | ↗ |
| 2020-07-10 | Marshall Randall | 10% Owner | S-Sale | D | Common Stock | 2,659 | 27.41 | 72.9K | 651,361 | — | ↗ |
| 2020-06-09 | Solomon Michael Edward | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 35.00 | 315.0K | 9,000 | — | ↗ |
| 2020-06-09 | SARGEN GREGORY | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 35.00 | 315.0K | 9,000 | — | ↗ |
| 2020-06-09 | Levy Richard S | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 35.00 | 315.0K | 9,000 | — | ↗ |
| 2020-06-09 | GARCEAU ROGER | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 35.00 | 315.0K | 9,000 | — | ↗ |
| 2020-06-09 | Braunstein Scott | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 35.00 | 315.0K | 9,000 | — | ↗ |
| 2020-06-09 | BESHAR LUKE M | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 35.00 | 315.0K | 9,000 | — | ↗ |
| 2020-02-11 | Davis Blaine | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-01-10 | Zummo Jacqueline | Officer | A-Award | A | Common Stock | 45,500 | 0.00 | — | 74,113 | — | ↗ |
| 2020-01-10 | Solomon Michael Edward | Director | A-Award | A | Common Stock | 26,500 | 0.00 | — | 26,500 | — | ↗ |
Executive team
Top executives
Shares Outstanding
38.59M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jesse Shefferman President, Chief Executive Officer and Director | 654.9K | — | 294.5K | 1.28M | 351.2K | 78.0K | 2.66M | 59.18% | ↗ |
| 2 | 2025 | Leonardo Nicacio, M.D. Chief Medical Officer | 373.9K | 75.0K | 208.5K | 453.4K | 229.8K | 41.9K | 1.38M | 47.88% | ↗ |
| 3 | 2025 | Jacqueline Zummo, Ph.D. Chief R&D Officer | 494.0K | — | 111.0K | 481.8K | 219.5K | 75.9K | 1.38M | 42.89% | ↗ |
| 4 | 2024 | Jesse Shefferman President, Chief Executive Officer and Director | 632.3K | — | 112.7K | 542.6K | 432.9K | 71.3K | 1.79M | 36.57% | ↗ |
| 5 | 2024 | Jesse Shefferman President, Chief Executive Officer and Director | 632.3K | — | 112.7K | 542.6K | 432.9K | 71.3K | 1.79M | 36.57% | ↗ |
| 6 | 2024 | Jacqueline Zummo, Ph.D. Chief Scientific Operations Officer | 475.8K | 150.0K | 43.9K | 208.2K | 266.1K | 70.2K | 1.21M | 20.77% | ↗ |
| 7 | 2024 | Jacqueline Zummo, Ph.D. Chief R&D Officer | 475.8K | 150.0K | 43.9K | 208.2K | 266.1K | 70.2K | 1.21M | 20.77% | ↗ |
| 8 | 2024 | Jathin Bandari, M.D. | 135.4K | 150.0K | 43.9K | 208.2K | — | 543.7K | 1.08M | 23.32% | ↗ |
| 9 | 2024 | Patrick Fabbio Chief Financial Officer | 465.0K | — | 42.0K | 199.1K | 260.3K | 57.1K | 1.02M | 23.56% | ↗ |
| 10 | 2023 | Jesse Shefferman President, Chief Executive Officer and Director | 607.9K | — | 154.9K | 736.1K | 341.4K | 65.8K | 1.91M | 46.75% | ↗ |
| 11 | 2023 | Patrick Fabbio Chief Financial Officer | 412.9K | 25.0K | — | 746.9K | 206.8K | 52.0K | 1.44M | 51.74% | ↗ |
| 12 | 2023 | Patrick Fabbio Chief Financial Officer | 412.9K | 25.0K | — | 746.9K | 206.8K | 52.0K | 1.44M | 51.74% | ↗ |
| 13 | 2023 | Jacqueline Zummo, Ph.D. Chief Scientific Operations Officer | 432.4K | — | 60.1K | 285.6K | 200.6K | 61.1K | 1.04M | 33.24% | ↗ |
| 14 | 2022 | Jesse Shefferman President, Chief Executive | 587.6K | — | 291.9K | 1.38M | 460.1K | 63.9K | 2.78M | 60.03% | ↗ |
| 15 | 2022 | Jesse Shefferman President, Chief Executive Officer and Director | 587.6K | — | 291.9K | 1.38M | 460.1K | 63.9K | 2.78M | 60.03% | ↗ |
| 16 | 2022 | Blaine Davis Former Chief Financial | 228.7K | — | 97.3K | 460.8K | — | 599.5K | 1.39M | 40.26% | ↗ |
| 17 | 2022 | Jacqueline Zummo, Ph.D. Chief Scientific Operations Officer | 417.8K | — | 97.3K | 460.8K | 264.2K | 61.7K | 1.30M | 42.87% | ↗ |
| 18 | 2022 | Jacqueline Zummo, Ph.D. Chief Scientific Operations | 417.8K | — | 97.3K | 460.8K | 264.2K | 61.7K | 1.30M | 42.87% | ↗ |
| 19 | 2022 | Jathin Bandari, M.D. | 414.5K | — | 84.6K | 400.4K | 260.0K | 13.4K | 1.17M | 41.36% | ↗ |
| 20 | 2021 | Jesse Shefferman President, Chief Executive | 570.0K | — | — | 3.11M | 328.0K | 58.8K | 4.07M | 76.48% | ↗ |
| 21 | 2021 | Jacqueline Zummo, Ph.D. Chief Scientific Operations Officer | 405.4K | — | — | 1.16M | 169.3K | 57.0K | 1.79M | 64.65% | ↗ |
| 22 | 2021 | Jacqueline Zummo, Ph.D. Chief Scientific Operations | 405.4K | — | — | 1.16M | 169.3K | 57.0K | 1.79M | 64.65% | ↗ |
| 23 | 2021 | Blaine Davis Former Chief Financial | 409.3K | — | — | 1.16M | 170.8K | 14.5K | 1.75M | 66.02% | ↗ |
| 24 | 2021 | Blaine Davis Chief Financial Officer | 409.3K | — | — | 1.16M | 170.8K | 14.5K | 1.75M | 66.02% | ↗ |
| 25 | 2020 | Jesse Shefferman President, Chief Executive Officer and Director | 506.7K | — | 1.50M | 5.00M | 694.5K | 54.7K | 7.76M | 83.81% | ↗ |
| 26 | 2020 | Jesse Shefferman President, Chief Executive | 506.7K | — | 1.50M | 5.00M | 694.5K | 54.7K | 7.76M | 83.81% | ↗ |
| 27 | 2020 | Blaine Davis Chief Financial Officer | 343.4K | — | — | 2.79M | 236.4K | 12.3K | 3.38M | 82.50% | ↗ |
| 28 | 2020 | Julio Casoy, M.D. Former Chief Medical Officer | 234.1K | — | 1.37M | — | 115.5K | 464.1K | 2.18M | 62.62% | ↗ |
| 29 | 2020 | Jacqueline Zummo, Ph.D. Chief Scientific Operations Officer | 324.9K | — | 1.37M | — | 269.9K | 31.3K | 1.99M | 68.55% | ↗ |
| 30 | 2020 | Jacqueline Zummo, Ph.D., MPH, MBA Chief Scientific Operations Officer | 324.9K | — | 1.37M | — | 269.9K | 31.3K | 1.99M | 68.55% | ↗ |
| 31 | 2019 | Timothy Noyes Former President, Chief Executive Officer and Director | 411.3K | — | — | 710.0K | — | 561.2K | 1.68M | 42.20% | ↗ |
| 32 | 2019 | George Eldridge Former Chief Financial Officer | 377.3K | — | — | 288.0K | 151.1K | 445.3K | 1.26M | 22.83% | ↗ |
| 33 | 2019 | Steven Burke, M.D. Former Chief Medical Officer | 262.0K | — | — | 288.0K | — | 452.7K | 1.00M | 28.72% | ↗ |
| 34 | 2019 | Julio Casoy, M.D. Chief Medical Officer | 348.5K | — | — | 255.9K | — | 18.1K | 622.5K | 41.11% | ↗ |
| 35 | 2019 | Julio Casoy, M.D. Former Chief Medical Officer | 348.5K | — | — | 255.9K | — | 18.1K | 622.5K | 41.11% | ↗ |
| 36 | 2019 | Jesse Shefferman President, Chief Executive Officer and Director | 343.6K | — | — | — | — | 35.5K | 379.1K | 0.00% | ↗ |
| 37 | 2019 | Jacqueline Zummo, Ph.D., MPH, MBA Chief Scientific Operations Officer | 289.4K | — | — | 47.1K | — | 17.2K | 353.7K | 13.31% | ↗ |
| 38 | 2019 | Jacqueline Zummo, Ph.D., MPH, MBA Senior Vice President, Research Operations | 289.4K | — | — | 47.1K | — | 17.2K | 353.7K | 13.31% | ↗ |
| 39 | 2019 | Blaine Davis Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 40 | 2018 | Timothy Noyes Former President, Chief Executive Officer and Director | 531.9K | — | — | 829.2K | 266.0K | 3.9K | 1.63M | 50.84% | ↗ |
| 41 | 2018 | Steven Burke, M.D. Former Chief Medical Officer | 434.9K | — | — | 439.4K | 174.0K | 4.9K | 1.05M | 41.72% | ↗ |
| 42 | 2018 | George Eldridge Former Chief Financial Officer | 365.0K | — | — | 439.4K | 142.4K | 2.3K | 949.1K | 46.30% | ↗ |
| 43 | 2018 | Jacqueline Zummo, Ph.D., MPH, MBA Senior Vice President, Research Operations | 185.2K | 56.3K | — | 192.5K | — | 16.8K | 450.7K | 42.71% | ↗ |
| 44 | 2018 | Jesse Shefferman President, Chief Executive Officer and Director | 268.0K | — | — | — | — | 32.8K | 300.8K | 0.00% | ↗ |
| 45 | 2018 | Julio Casoy, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 46 | 2017 | Timothy P. Noyes Chief Executive Officer and President | 501.8K | — | — | — | 263.4K | 4.2K | 978.2K | 0.00% | ↗ |
| 47 | 2017 | Steven K. Burke, M.D . Senior Vice President and Chief Medical Officer | 420.2K | — | — | — | 176.5K | 4.2K | 691.2K | 0.00% | ↗ |
| 48 | 2017 | George A. Eldridge Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 352.7K | — | — | — | 141.1K | 2.6K | 586.7K | 0.00% | ↗ |
| 49 | 2016 | Timothy P. Noyes Chief Executive Officer and President | 487.2K | — | — | — | 243.6K | 4.7K | 735.5K | 0.00% | ↗ |
| 50 | 2016 | Steven K. Burke, M.D . Senior Vice President and Chief Medical Officer | 408.0K | — | — | — | 142.8K | 5.7K | 556.5K | 0.00% | ↗ |
| 51 | 2016 | George A. Eldridge Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 323.0K | — | — | — | 113.1K | 3.0K | 439.0K | 0.00% | ↗ |
| 52 | 2016 | Timothy P. Noyes President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 53 | 2016 | George A. Eldridge Senior Vice President, Chief Financial Officer, Treasurer and Assistant Secretary | — | — | — | — | — | — | — | — | ↗ |
| 54 | 2016 | Steven K. Burke, M.D. Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 55 | 2015 | Timothy P. Noyes Chief Executive Officer and President | 473.0K | — | — | — | 236.5K | 4.7K | 2.98M | 0.00% | ↗ |
| 56 | 2015 | Steven K. Burke, M.D . Senior Vice President and Chief Medical Officer | 378.1K | — | — | — | 132.3K | 5.7K | 1.61M | 0.00% | ↗ |
| 57 | 2015 | George A. Eldridge Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 313.6K | — | — | — | 109.8K | 2.9K | 1.16M | 0.00% | ↗ |
| 58 | 2015 | Timothy P. Noyes President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 59 | 2015 | George A. Eldridge Senior Vice President, Chief Financial Officer, Treasurer and Assistant Secretary | — | — | — | — | — | — | — | — | ↗ |
| 60 | 2015 | Steven K. Burke, M.D. Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 61 | 2014 | Timothy P. Noyes Chief Executive Officer and President | 408.2K | — | — | — | 130.1K | 4.7K | 1.52M | 0.00% | ↗ |
| 62 | 2014 | George A. Eldridge Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 289.4K | — | — | 418.0K | 80.8K | 2.5K | 790.8K | 52.86% | ↗ |
| 63 | 2014 | Steven K. Burke, M.D . Senior Vice President and Chief Medical Officer | 369.1K | — | — | — | 98.9K | 5.7K | 753.9K | 0.00% | ↗ |
| 64 | 2014 | George A. Eldridge Senior Vice President, Chief Financial Officer, Treasurer and Assistant Secretary | — | — | — | — | — | — | — | — | ↗ |
| 65 | 2013 | Timothy P. Noyes Chief Executive Officer and President | 393.7K | — | — | — | 73.8K | 4.6K | 472.1K | 0.00% | ↗ |
| 66 | 2013 | Steven K. Burke, M.D . Senior Vice President and Chief Medical Officer | 359.9K | — | — | — | 81.0K | 5.6K | 446.5K | 0.00% | ↗ |
| 67 | 2013 | George A. Eldridge Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 85.7K | — | — | — | 17.6K | 576.00 | 103.8K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jesse Shefferman | Co-founder, Chief Executive Officer, President & Director | 1M | male |
| Leonardo Viana Nicacio | Chief Medical Officer | 872.3K | — |
| Jacqueline Zummo | Co-Founder, Chief R&D Officer | 789.4K | — |
| Patrick Fabbio | Chief Financial Officer | 782.4K | male |
| Neal D. Shore | Medical Director of START Carolinas/ Carolina Urologic Research Center | — | — |
| Shane Williams | Chief People Officer | — | — |
| Carla Beckham | Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist | — | — |
| William Conkling | Chief Commercial Officer | — | male |
| Hannah Fry | Vice President, Principal Accounting Officer & Controller | — | female |
| Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs | — | female |
| Mary J. Grendell | General Counsel & Corporate Secretary | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TARA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
